Gsa Capital Partners LLP Intellia Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$20.02 - $27.22 $1.41 Million - $1.92 Million	70,355 New	70,355 $1.58 Million
Q4 2022 Feb 13, 2023	BUY	$33.21 - $62.69 $131,113 - $247,500	3,948 Added 37.94%	14,355 $501,000
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $561,145 - $746,181	10,407 New	10,407 $582,000
Q1 2020 May 12, 2020	SELL	$9.44 - $15.58 $316,551 - $522,444	-33,533 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$10.43 - $17.67 $349,749 - $592,528	33,533 New	33,533 $492,000
Q3 2019 Nov 12, 2019	SELL	$13.07 - $18.51 $399,353 - $565,573	-30,555 Closed	0 $0
Q2 2019 Aug 06, 2019	BUY	$13.88 - $18.41 $280,112 - $371,532	20,181 Added 194.53%	30,555 $500,000
Q1 2019 May 15, 2019	BUY	$12.79 - $17.62 $132,683 - $182,789	10,374 New	10,374 $177,000
Q2 2018 Aug 09, 2018	SELL	$20.02 - $30.79 $1.04 Million - $1.6 Million	-51,900 Closed	0 $0
Q1 2018 May 11, 2018	BUY	$19.43 - $34.95 $1.01 Million - $1.81 Million	51,900 New	51,900 $1.1 Million
Q4 2017 Feb 14, 2018	SELL	$17.39 - $31.12 $1.27 Million - $2.27 Million	-73,100 Closed	0 $0
Q3 2017 Nov 20, 2017	BUY	$15.16 - $25.75 $1.11 Million - $1.88 Million	73,100	73,100 $1.82 Million

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $926M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.